FundedIQ
Artificial Intelligence

CytoVale

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Sepsis, a dysregulated immune response to infection, is often difficult to quickly and accurately diagnose. Sepsis is the no. 1 cause of death in hospitals, taking the lives of 270,000 people every year in the U.S. – more than opioid overdoses, prostate cancer, and breast cancer combined. Mortality from sepsis increases as much as eight percent with every hour of delayed treatment, and as much as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment, making early detection essential. Cytovale aims to provide critical insight for early identification of patients at risk of having sepsis, in the time needed for it to be useful. Follow us on Twitter: twitter.com/cytovale Subscribe to our newsletter: http://eepurl.com/huCdiH

www.cytovale.com San Francisco, United States 11-50 employees
Total raised
$184M
Latest round: +119% of prior total
Rounds
2
Latest
Series D
Oct 2024

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Sepsis, a dysregulated immune response to infection, is often difficult to quickly and accurately diagnose. Sepsis is the no. 1 cause of death in hospitals, taking the lives of 270,000 people every year in the U.S. – more than opioid overdoses, prostate cancer, and breast cancer combined. Mortality from sepsis increases as much as eight percent with every hour of delayed treatment, and as much as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment, making early detection essential. Cytovale aims to provide critical insight for early identification of patients at risk of having sepsis, in the time needed for it to be useful. Follow us on Twitter: twitter.com/cytovale Subscribe to our newsletter: http://eepurl.com/huCdiH

CytoVale has raised $184M across 2 rounds. Its most recent round was a Series D of $100M in Oct 2024. Full funding history, investors, and team are detailed below.

Funding history

2 rounds · 1 visible Unlock with plan

2 rounds on record — latest round shown, the rest unlock with a paid plan.

Date
Round
Amount
Lead investor
Oct 10, 2024
Series D
$100M

Unlock 1 earlier round — dates, amounts, round types — plus the lead investor for every round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

CytoVale is featured in

Similar companies

Verisoul

Verisoul is a company that designs a decentralized platform with artificial intelligence, aiming to aid businesses in combating the presence of fraudulent users. By merging anonymity and accountability, Verisoul collaborates with Web3 developers to enable them in identifying reliable users while distinguishing them from scammers, bots, and imposters.

Venture - Series Unknown $7.3M
Model ML

Model ML is an AI tool that improves workflows for investment banks and private equity firms by integrating multiple data sources for research and due diligence, with the goal of revolutionizing the finance industry with a more efficient AI workspace.

Series A $75.0M
Apptronik

Apptronik fabricates and plans human-focused mechanical technology frameworks.

Venture - Series Unknown $331M
Momentic

Momentic allows developers to deploy AI agents to test the complete functionality of web applications by simply describing user flows in a natural language.

Series A $15.0M
Harmonic

The company Harmonic creates Mathematical Superintelligence (MSI), a cutting-edge artificial intelligence system grounded in mathematical principles to ensure precision and eliminate errors.

Series C $120M
Scale Social AI

Scale Social is an AI-powered marketing platform that automates capturing, curating, and distributing customer-generated content. It is specifically designed to help small businesses drive growth through authentic, high-impact digital marketing.

Pre-Seed $1.3M
Federato

Federato's RiskOps underwriting platform for insurance carriers, MGAs and MGUs provides real-time risk selection and portfolio insights to empower underwriters to balance their book of business and make better underwriting decisions.

Series D $100M
Kalshi

Kalshi is a financial exchange that is regulated by the government and allows investors to trade based on their predictions of future events. The markets offered by Kalshi cover various topics such as economics, international affairs, media, entertainment, climate, and public health. Unlike traditional instruments like stocks or bonds, Kalshi's markets are more specific, giving investors direct exposure to events and trends they are interested in. For example, a market on the signing of a free trade agreement can help retail investors gain exposure to emerging markets and changes in international trade. Check out their website at https://kalshi.com.

Venture - Series Unknown $1.0B
Suno

Suno is a music startup that allows individuals to create the music they desire, with the goal of helping people find pleasure in play and discovery once again.

Series C $250M
Numeric

Organizations trust Numeric to guarantee the accuracy of their financial information, streamline the month-end closing process, and provide immediate insights. With a rating of 4.9 out of 5 on G2.

Series B $51.0M
AI Proteins

AI Proteins is a biotechnology company that focuses on the design and engineering of synthetic mini protein therapeutics. The company was founded in 2021 and is headquartered in Boston, Massachusetts.

Series A $41.5M
Luma AI

Luma is an AI company building the future of 3D.

Series C $900M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.